Aileron Therapeutics, Inc. (NASDAQ:ALRN) Position Boosted by Geode Capital Management LLC

Geode Capital Management LLC lifted its stake in shares of Aileron Therapeutics, Inc. (NASDAQ:ALRN) by 34.8% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 229,817 shares of the company’s stock after purchasing an additional 59,370 shares during the period. Geode Capital Management LLC’s holdings in Aileron Therapeutics were worth $814,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. KG&L Capital Management LLC bought a new position in Aileron Therapeutics in the third quarter worth about $46,000. Warberg Asset Management LLC bought a new position in Aileron Therapeutics in the second quarter worth about $86,000. Sigma Planning Corp lifted its holdings in Aileron Therapeutics by 68.3% in the third quarter. Sigma Planning Corp now owns 212,410 shares of the company’s stock worth $752,000 after acquiring an additional 86,185 shares during the last quarter. Nantahala Capital Management LLC lifted its holdings in Aileron Therapeutics by 82.1% in the second quarter. Nantahala Capital Management LLC now owns 464,367 shares of the company’s stock worth $1,286,000 after acquiring an additional 209,367 shares during the last quarter. Finally, University of Texas Texas AM Investment Management Co. bought a new position in Aileron Therapeutics in the second quarter worth about $4,925,000. Institutional investors own 90.89% of the company’s stock.

Aileron Therapeutics Stock Up 9.3 %

Shares of NASDAQ ALRN opened at $2.11 on Friday. The firm’s 50-day moving average price is $2.60 and its two-hundred day moving average price is $2.81. Aileron Therapeutics, Inc. has a 52-week low of $1.61 and a 52-week high of $7.42. The stock has a market capitalization of $45.72 million, a P/E ratio of -0.68 and a beta of 2.24.

Aileron Therapeutics Profile

Aileron Therapeutics, Inc, a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).